BAO PHARMA-B(02659.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
BAO PHARMA-B
02659.HK
Shanghai Bao Pharmaceuticals Co., Ltd. is a clinical-stage biotechnology company uses synthetic biology technology to develop and deliver recombinant biologic drugs in Mainland China, Hong Kong, Macau, and Taiwan. Its products includes KJ017, a recombinant human hyaluronidase; KJ103, an recombinant immunoglobulin G (IgG)-degrading enzyme; SJ02, a long-acting recombinant human follicle-stimulating hormone carboxyl-terminal peptide fusion protein (FSH-CTP); BJ044, a recombinant ulinastatin developed through synthetic biology; BJ007, a SC administered ceftriaxone sodium for the treatment of bacterial infections; and KJ101, a recombinant human chymotrypsin developed through synthetic biology. The company also develops drug design platform, chassis cell engineering platform, and comprehensive bioprocessing platform.
1.309 T
02659.HKMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Morning Trend | BAO PHARMA-B experiences low-volume fluctuations, can the innovative drug concept bring new vitality?

    Yesterday, the innovative drug sector performed moderately overall, with BAO PHARMA-B (2659.HK) maintaining a pattern of reduced volume consolidation. Throughout the day, market liquidity was limited, lacking significant signals of capital involvement. Influenced by news related to innovative drugs, there were occasional spikes during the trading session, but they quickly retreated. The company has no major announcements to drive momentum, and signs of main force positioning are not evident. From an industry perspective, the innovative drug direction is favored by capital in the medium to long term, but short-term hotspots are mostly focused on leading enterprises with news catalysts. BAO PHARMA lacks positive drivers, and its current premium capability is limited, with local rebounds primarily driven by short-term funds. The market is frequently adjusting positions, with funds mainly engaged in existing stock games. Major technical indicators are slightly strengthening at the margins, and bottom funds are tentatively testing, but the overall pattern leans towards a wait-and-see approach. Insufficient liquidity and dispersed main forces result in low volatility, and future performance still needs to pay attention to new news or sector movements. The inclination for flexible wave trading is increasing, and heavy position risks need to be continuously monitored. It is recommended to pay attention to news in the innovative drug industry and changes in company announcements. If positive catalysts appear, it may drive funds to re-enter

    Technical Forecast·
    HK
    02659
    -2.39%
    Technical Forecast·
    HK
    02659
    -2.39%

    Top 10 HK Stock Losers (1.2)

    CLOUDBREAK-B(02592) fell 13.27%, with a trading turnover 21.6 Million HKD, and a year-to-date fell 55.3%. 361 DEGREES(01361) fell 11.22%, with a trading turnover 111.7 Million HKD, and a year-to-date rose 37.4%. BAO PHARMA-B(02659) fell 10.12%, with a trading turnover 27.9 Million HKD, and a year-to-date rose 164.2%.

    Top Gainers & Losers·
    HK
    02592
    -1.97%
    HK
    01361
    -1.05%
    HK
    02659
    -2.39%
    Top Gainers & Losers·
    HK
    02592
    -1.97%
    HK
    01361
    -1.05%
    HK
    02659
    -2.39%

    Hong Kong Stock Movement: BAO PHARMA-B fell 11.80%, full circulation plan raises concerns about overvaluation and market uncertainty

    BAO PHARMA-B fell 11.80%; Innovent Biologics rose 3.28%, with a transaction volume of HKD 198 million; BeiGene rose 2.68%, with a transaction volume of HKD 99.86 million; 3SBio rose 1.49%, with a transaction volume of HKD 78.43 million; CanSino Biologics rose 0.18%, with a market capitalization of HKD 104.3 billion

    HK Stock Movers Tracker·
    HK
    02659
    -2.39%
    HK Stock Movers Tracker·
    HK
    02659
    -2.39%

    Hong Kong stock movement quick report: GOLDWIND leads with a 17% increase, SYNAGISTICS and ALMANA both rise, while CHINA CBM plummets by 20%

    Hong Kong stock market overview in the past hour: Market sentiment has experienced significant fluctuations in a short period, with the energy and technology sectors standing out. The sharp decline of China Coalbed Methane has attracted widespread attention, suggesting that funds are withdrawing from the energy sector, while the strong rise of Goldwind indicates a market preference for green energy. Meanwhile, the pharmaceutical sector shows a clear divergence in performance, with some individual stocks under pressure, reflecting a cautious attitude from investors. In the past hour, the stock with the largest abnormal movement, China Coalbed Methane, saw a decline of 20.63%, becoming the focus of market attention. The rapid withdrawal of funds has put pressure on the stock price, and market sentiment appears tense, with investors taking a wait-and-see approach regarding the future trend of this stock. Strong stocks: 1. Goldwind: up 17.67%, the green energy concept is favored by the market, with significant fund inflow. 2. Synagistics: up 17.61%, short-term funds are active, and market sentiment is high. 3. Almana: up 15.54%, increased fund attention, and stock price volatility has intensified. 4. DL Holdings GP: up 10.78%, the market holds an optimistic view on its future development, with significant fund inflow. 5. GD-HKGBA HLDGS: up 10.47%, the regional development concept is attracting market attention, with active fund inflow. Stocks under pressure: 1. POWERWIN TECH: down 15.38%, the market holds a cautious view on its future development, with significant fund outflow. 2. CH ENV TECH&BIO: down 14.00%, the pharmaceutical sector shows clear divergence, with significant signs of fund withdrawal

    HK Stock Movers Tracker·
    HK
    08270
    +15.38%
    HK
    02208
    -2.90%
    HK
    02562
    -2.89%
    HK Stock Movers Tracker·
    HK
    08270
    +15.38%
    HK
    02208
    -2.90%
    HK
    02562
    -2.89%

    Hong Kong Stock Movement: BAO PHARMA-B's full circulation plan triggers a sharp decline in stock price, as the market reassesses liquidity and valuation risks

    BAO PHARMA-B fell 10.06%; Innovent Biologics rose 2.62%, with a transaction volume of HKD 120 million; BeiGene rose 2.45%, with a transaction volume of HKD 63.77 million; CanSino Biologics fell 1.06%, with a transaction volume of HKD 50.03 million; Kelun-Biotech rose 0.71%, with a market capitalization of HKD 92.1 billion

    HK Stock Movers Tracker·
    HK
    02659
    -2.39%
    HK Stock Movers Tracker·
    HK
    02659
    -2.39%
    © 2026 Longbridge｜Disclaimer